Navista names Jeff Hunnicutt COO, bringing in a well-known oncology leader with experience in technology and innovation at the practice level. Jeff Hunnicutt, fresh off 8 years as CEO of Highlands ...

Giredestrant plus Afinitor improved disease control after later treatment and delayed chemotherapy in ER-positive, HER2-negative breast cancer. Treatment with giredestrant plus Afinitor (everolimus) ...

Marstacimab is the first subcutaneous option for hemophilia B, reducing reliance on frequent IV infusions and improving patient quality of life. The phase 3 BASIS trial showed marstacimab reduced ...

Erika Hamilton, MD, discussed findings from the phase 1b/2 ELECTRA study investigating a new oral combination therapy for patients with metastatic breast cancer. While endocrine therapy plus CDK4/6 ...

Deep learning vs traditional breast cancer risk assessment models: Are we offering supplemental services to those who benefit the most? This is an ASCO Meeting Abstract from the 2024 ASCO Annual ...

Enhancing GPT-4 with meta-prompting. In this study, we introduce and examine the effectiveness of meta- prompting, contrasting it with a range of zero-shot prompting techniques, including standard ...

Abstract: Minimally invasive surgery (MIS) has evolved as an effective method for cardiovascular diseases (CVDs) and gastrointestinal (GI) cancers. Recently, soft robotic catheters using soft ...

Abstract: The edge–cloud continuum combines heterogeneous resources, which are complex to manage. Serverless edge computing is a suitable candidate to manage the continuum by abstracting away the ...

Ken Van Haren and Chris Stanley were data scientists at Google and Square, respectively, who found themselves frustrated by how much time they were spending wrangling infrastructure versus doing ...

NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), National University of Singapore, Singapore 117456, Singapore Synthetic Biology Translational Research Programme, Yong Loo Lin ...